Home » UCB, Novartis Ink Licensing Deal for German Market
UCB, Novartis Ink Licensing Deal for German Market
Belgian pharmaceutical group UCB and Swiss drugmaker Novartis have entered a licensing agreement for cardiovascular and diabetes products in Germany, UCB said in a statement on Monday.
Forbes
Forbes
Upcoming Events
-
07May
-
14May
-
30May